课题基金 / 基金详情

Assay Development

Assay Development
检测开发
批准号:
8379686
负责人:
Eduard A. Sergienko
金额:
$262.56万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2014-05-31

项目摘要

项目成果

Eduard A. Sergienko的其他基金

相似基金

相关文献

中文摘要
翻译
第一单元.试验开发、调整和实施 单元1负责所有检测活动以及HTS命中后表征,执行:(a) HTS和HCS的测定开发和适应性,(B)通过验证性分析对命中进行初始表征 测定和EC 50/IC 50测定,(c)二级和正交测定和筛选,(d)类似物的测试 和化学优化的化合物,以及(e)关于命中和优化的初步作用模式研究 化合物.第1单元通过开发和调整36个初级HTS,超过了MLSCN的目标 由各种读数组成的分析,迄今为止进行了39次筛查活动。该股还 开发了27个二级/计数器分析,以支持MLSCN项目。此外,该股还支助了22次打击 优化/SAR项目使用41个剂量-反应测定,生成了> 24,000个IC 50 10点曲线, 重复并进行了>20项作用方式研究。第1单元分为两个子单元:子单元1A将 开发和实施所有HTS检测,而子单位1B负责开发和优化软件 HCS的算法。
英文摘要
UNIT 1. ASSAY DEVELOPMENT, ADAPTATION, AND IMPLEMENTATION Unit 1 is a responsible for all assay activities, as well as for post-HTS hit characterization, performing: (a) assay development and adaptation for HTS and HCS, (b) initial characterization of hits through confirmatory assays and ECso/ICsq determination, (c) secondary and orthogonal assays and screens, (d) testing of analogs and chemistry-optimized compounds, and (e) preliminary mode-of-action studies on hits and optimized compounds. Unit 1 surpassed the MLSCN goals with the development and adaptation of 36 primary HTS assays consisting of a variety of read-outs, resulting in 39 screening campaigns thus far. The Unit also developed 27 secondary/counter assays to support the MLSCN projects. Additionally, the Unit supported 22 hit optimization/SAR projects using 41 dose-response assays, generated >24,000 IC50 10-point curves in duplicate and performed >20 mode-of-action studies. Unit 1 is organized into two subunits: subunit 1A will develop and implement all HTS assays, while subunit 1B is responsible for developing and optimizing software algorithms for HCS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Assay Development
Assay Development
海外基金